Biotech Values

[geocappy1]

I don't think anyone is saying that with absolute certainty but it also may be unlikely to expect dramatic differences in OS from the two different chem agents used in the bavi 1st and 2nd-line trials. So, what jq posted is a caveat that you have to consider.

That is good because no one knows for sure. Thorpe has said Doce is better due to its affect on exposing PS. Secondly, although the ORR and PFS did not appear to differentiate themselves much from the control group in 1st line, the MOS has not been determined yet. The enrollment in 1st line was completed almost 12 months ago and the MOS may not be triggered til later in 2012 which would be some 15 months from enrollment completion. I believe there is some examples in trial data out there where the MOS results do not necessarily correlate to ORR and PFS both for and against.

So let's just say that 1st line MOS using bavi/CP come in above SOC (12.4 months) and 2nd line Bavi/Doce come in at 13 months (4 months better than SOC and more than double control arm).

Would it still be a placebo? Time will tell. Shouldn't be long now.